Tumor Metabolism, the Ketogenic Diet and β-Hydroxybutyrate: Novel Approaches to Adjuvant Brain Tumor Therapy
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Malignant brain tumors are devastating despite aggressive treatments such as surgical resection, chemotherapy and radiation therapy. The average life expectancy of patients with newly diagnosed glioblastoma is approximately ~18 months. It is clear that increased survival of brain tumor patients requires the design of new therapeutic modalities, especially those that enhance currently available treatments and/or limit tumor growth. One novel therapeutic arena is the metabolic dysregulation that results in an increased need for glucose in tumor cells. This phenomenon suggests that a reduction in tumor growth could be achieved by decreasing glucose availability, which can be accomplished through pharmacological means or through the use of a high-fat, low-carbohydrate ketogenic diet (KD). The KD, as the name implies, also provides increased blood ketones to support the energy needs of normal tissues. Preclinical work from a number of laboratories has shown that the KD does indeed reduce tumor growth in vivo. In addition, the KD has been shown to reduce angiogenesis, inflammation, peri-tumoral edema, migration and invasion. Furthermore, this diet can enhance the activity of radiation and chemotherapy in a mouse model of glioma, thus increasing survival. Additional studies in vitro have indicated that increasing ketones such as β-hydroxybutyrate in the absence of glucose reduction can also inhibit cell growth and potentiate the effects of chemotherapy and radiation. Thus, while we are only beginning to understand the pluripotent mechanisms through which the KD affects tumor growth and response to conventional therapies, the emerging data provide strong support for the use of a KD in the treatment of malignant gliomas. This has led to a limited number of clinical trials investigating the use of a KD in patients with primary and recurrent glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 2×
“…and Thompson, 2012; Semenza, 2013; Gaude and Frezza, 2014; Masson and Ratcliffe, 2014; Boroughs and DeBerardinis, 2015; Casey et al., 2015; Robey et al., 2015; Asati et al., 2016; Barron et al., 2016; Bost et al., 2016; Molon et al., 2016; Pavlova and Thompson, 2016; PérezEscuredo et al., 2016).”
BackgroundThe metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 4×
“Although some of these interactions are mentioned above, in-depth discussions of all of the interactions that occur between cancer and metabolism are beyond the scope of this review and the reader is referred to a number of reviews on these subjects (Gatenby and Gillies, 2004; Vander Heiden et al., 2009; Cantor and Sa…”
BackgroundInfluentialThe ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease
Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D'Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3804 · Cited by 2,172
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · cited 1×
“…to the tumor microenvironment which not only affects tumor cell growth, but also response to therapy (Yamada et al., 1999; Joon et al., 2004; Amberger-Murphy, 2009; Dewhirst, 2009; Hattingen et al., 2011; Metallo et al., 2011; Yang et al., 2012; Danhier et al., 2013; Justus et al., 2015).”
BackgroundSuppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335 · cited 1×
“…to a number of reviews on these subjects (Gatenby and Gillies, 2004; Vander Heiden et al., 2009; Cantor and Sabatini, 2012; Ward and Thompson, 2012; Semenza, 2013; Gaude and Frezza, 2014; Masson and Ratcliffe, 2014; Boroughs and DeBerardinis, 2015; Casey et al., 2015; Robey et al., 2015; Asati et…”
BackgroundKetone bodies as signaling metabolites
Newman, J. C., & Verdin, E. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.002 · Cited by 966 · cited 2×
“The use ofmetabolic alteration for the therapy of brain tumors has been championed by Seyfried et al. (2011).”
BackgroundMethodHypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001115 · Cited by 725
Raffaghello, L., Lee, C., Safdie, F. M., Wei, M., Madia, F., Bianchi, G., & Longo, V. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708100105 · Cited by 587 · cited 1×
“…short-term fasting have also been found to be synergistic with radiation and other anti-cancer therapeutics in both preclinical and clinical studies (Raffaghello et al., 2008, 2010; Lee et al., 2010, 2012; Safdie et al., 2012; Champ et al., 2013, 2014; Saleh et al., 2013; Klement and Champ, 2014).”
BackgroundNeuroprotective and disease-modifying effects of the ketogenic diet
Gasior, M., Rogawski, M. A., & Hartman, A. L. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00009 · Cited by 445
Kashiwaya, Y., Bergman, C., Lee, J.-H., Wan, R., King, M. T., Mughal, M. R., Okun, E., Clarke, K., Mattson, M. P., & Veech, R. L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.023 · Cited by 363 · cited 1×
“…evidence for this comes from data showing that the use of ketone supplementation can enhance the effects of the KD and may even be effective in some diseases when used alone (Veech, 2004, 2014; Kashiwaya et al., 2013; Poff et al., 2014; Shukla et al., 2014; Newport et al., 2015; Youm et al., 2015).”
BackgroundThe Role of p53 in Metabolic Regulation
Puzio-Kuter, A. M. (2011) · Genes & Cancer · doi:10.1177/1947601911409738 · Cited by 273 · cited 1×
“…pivotal role in the cellular responses to hypoxia, DNA damage and oncogene activation is now known to regulate glycolysis and assist in maintaining mitochondrial integrity (Olovnikov et al., 2009; Madan et al., 2011; Puzio-Kuter, 2011; Kim and Kim, 2013; Iurlaro et al., 2014; Barron et al., 2016).”
BackgroundLactate promotes glutamine uptake and metabolism in oxidative cancer cells
Pérez-Escuredo, J., Dadhich, R. K., Dhup, S., Cacace, A., Van Hée, V. F., De Saedeleer, C. J., Sboarina, M., Rodriguez, F., Fontenille, M.-J., Brisson, L., et al. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1120930 · Cited by 231
The evolution of genome-scale models of cancer metabolism
Lewis, N. E., & Abdel-Haleem, A. M. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00237 · Cited by 87
Cited by
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,610
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
Ferrere, G., Tidjani Alou, M., Liu, P., Goubet, A.-G., Fidelle, M., Kepp, O., Durand, S., Iebba, V., Fluckiger, A., Daillère, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145207 · Cited by 533
Nutrition, inflammation and cancer
Zitvogel, L., Pietrocola, F., & Kroemer, G. (2017) · Nature Immunology · doi:10.1038/ni.3754 · Cited by 446
A framework for examining how diet impacts tumour metabolism
Lien, E. C., & Vander Heiden, M. G. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0198-5 · Cited by 139
Ketogenic Diet Compromises Both Cancellous and Cortical Bone Mass in Mice
Wu, X., Huang, Z., Wang, X., Fu, Z., Liu, J., Huang, Z., Kong, G., Xu, X., Ding, J., & Zhu, Q. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0292-1 · Cited by 41
Metadata
- Authors
- Woolf, E. C., Syed, N., & Scheck, A. C.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2016-11-16
- Volume
- 9
- Pages
- 122-122
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W2552014047
- Cited by
- 123
- References
- 15
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.